Pharmaceuticals, Biotechnology and Life Sciences
Approval of expanded indication based predominately on real-world data NEW YORK–(BUSINESS WIRE)–Pfizer (NYSE:PFE) today announced that the U.S. Food and…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor…
German Merck, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer are dropping the Phase III JAVELIN Ovarian PARP 100 study in which they tested avelumab combined with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV), as they described in the press release on Wednesday.
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease Pfizer acquires 15% ownership stake in…
Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.
Basilea Pharmaceutica cahsed $5 million from Pfizer’s milestone payment triggered for selling of the antifungal Cresemba in Europe..
BioMarin Pharmaceutical has received $20 million in milestone payments from Pfizer Inc, it said Thursday.
The U.S. Food and Drug Administration today expanded the approval of Pfizer’s Xeljanz (tofacitinib), the first oral medication approved for…
Pfizer has appointed a professor of molecular immunology Dr. Dan R. Littman to its Board of Directors, was also appointed…
ViiV Healthcare on Thursday said it has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United…